Product Code: GMDHC9085IDB
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Pipeline Review, H1 2017, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.
Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 4, 20 and 10 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 9 molecules, respectively.
Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Candidiasis - Overview
- Candidiasis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Candidiasis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Candidiasis - Companies Involved in Therapeutics Development
- Amplyx Pharmaceuticals Inc
- Bakker Medical Srl
- Biomar Microbial Technologies
- Biosergen AS
- Cidara Therapeutics Inc
- CSA Biotechnologies LLC
- Daewoong Pharmaceutical Co Ltd
- Dermala Inc
- General Biologicals Corp
- Grupo Ferrer Internacional SA
- Hsiri Therapeutics LLC
- iCo Therapeutics Inc.
- ImmunoClin Corp
- Matinas BioPharma Holdings Inc
- Nanomerics Ltd
- NovaDigm Therapeutics Inc
- Novartis AG
- Onxeo SA
- Scynexis Inc
- Sealife PHARMA GMBH
- Viamet Pharmaceuticals Inc
- Visterra Inc
- Wellstat Vaccines LLC
- Candidiasis - Drug Profiles
- (clotrimazole + diclofenac sodium) - Drug Profile
- 61894700 - Drug Profile
- AC-17 - Drug Profile
- amphotericin B - Drug Profile
- amphotericin B - Drug Profile
- amphotericin B - Drug Profile
- Amphotericin B sodium - Drug Profile
- Antibody to Target Ece1 for Candidiasis - Drug Profile
- APX-001 - Drug Profile
- APX-001A - Drug Profile
- arasertaconazole - Drug Profile
- B-4010 - Drug Profile
- BL-5923 - Drug Profile
- BSG-005 - Drug Profile
- candidiasis vaccine - Drug Profile
- CD-101 - Drug Profile
- Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
- CSA-13 - Drug Profile
- Drug for Candidiasis - Drug Profile
- DWP-06081 - Drug Profile
- Forazoline A - Drug Profile
- iCo-010 - Drug Profile
- interleukin-22 - Drug Profile
- JSM-11 - Drug Profile
- KSL-W - Drug Profile
- miconazole nitrate - Drug Profile
- Monoclonal Antibodies for Candidiasis - Drug Profile
- Monoclonal Antibody for Candidiasis - Drug Profile
- Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections - Drug Profile
- mutanobactin A - Drug Profile
- NDV-3 - Drug Profile
- NDV-3A - Drug Profile
- NP-339 - Drug Profile
- obliquumol - Drug Profile
- Occidiofungin - Drug Profile
- P-113Du - Drug Profile
- P-113Tri - Drug Profile
- PAC-113 - Drug Profile
- Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile
- Prof-002 - Drug Profile
- Recombinant Enzyme for Candidiasis - Drug Profile
- Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile
- SCY-078 - Drug Profile
- SLP-0901 - Drug Profile
- SLP-0904 - Drug Profile
- Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
- Small Molecule for Fungal Infections - Drug Profile
- Small Molecules for Aspergillosis and Candidiasis - Drug Profile
- Small Molecules for Candidiasis - Drug Profile
- Small Molecules for Candidiasis - Drug Profile
- Small Molecules for Candidiasis - Drug Profile
- Small Molecules for Fungal Infections - Drug Profile
- Small Molecules for Fungal Infections - Drug Profile
- Small Molecules for Systemic Candidiasis - Drug Profile
- Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile
- Synthetic Peptides for Candidiasis - Drug Profile
- Synthetic Peptides for Infections Diseases and Oncology - Drug Profile
- TOL-463 - Drug Profile
- Vaccine to Target Ece1 for Candidiasis - Drug Profile
- Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile
- VIS-FNG - Drug Profile
- VT-1129 - Drug Profile
- VT-1161 - Drug Profile
- Candidiasis - Dormant Projects
- Candidiasis - Discontinued Products
- Candidiasis - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Number of Products under Development for Candidiasis, H1 2017
- Number of Products under Development by Companies, H1 2017
- Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
- Number of Products under Development by Universities/Institutes, H1 2017
- Products under Development by Companies, H1 2017
- Products under Development by Companies, H1 2017 (Contd..1), H1 2017
- Products under Development by Companies, H1 2017 (Contd..2), H1 2017
- Products under Development by Universities/Institutes, H1 2017
- Number of Products by Stage and Target, H1 2017
- Number of Products by Stage and Mechanism of Action, H1 2017
- Number of Products by Stage and Route of Administration, H1 2017
- Number of Products by Stage and Molecule Type, H1 2017
- Candidiasis - Pipeline by Amplyx Pharmaceuticals Inc, H1 2017
- Candidiasis - Pipeline by Bakker Medical Srl, H1 2017
- Candidiasis - Pipeline by Biomar Microbial Technologies, H1 2017
- Candidiasis - Pipeline by Biosergen AS, H1 2017
- Candidiasis - Pipeline by Cidara Therapeutics Inc, H1 2017
- Candidiasis - Pipeline by CSA Biotechnologies LLC, H1 2017
- Candidiasis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
- Candidiasis - Pipeline by Dermala Inc, H1 2017
- Candidiasis - Pipeline by General Biologicals Corp, H1 2017
- Candidiasis - Pipeline by Grupo Ferrer Internacional SA, H1 2017
- Candidiasis - Pipeline by Hsiri Therapeutics LLC, H1 2017
- Candidiasis - Pipeline by iCo Therapeutics Inc., H1 2017
- Candidiasis - Pipeline by ImmunoClin Corp, H1 2017
- Candidiasis - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
- Candidiasis - Pipeline by Nanomerics Ltd, H1 2017
- Candidiasis - Pipeline by NovaDigm Therapeutics Inc, H1 2017
- Candidiasis - Pipeline by Novartis AG, H1 2017
- Candidiasis - Pipeline by Onxeo SA, H1 2017
- Candidiasis - Pipeline by Scynexis Inc, H1 2017
- Candidiasis - Pipeline by Sealife PHARMA GMBH, H1 2017
- Candidiasis - Pipeline by Viamet Pharmaceuticals Inc, H1 2017
- Candidiasis - Pipeline by Visterra Inc, H1 2017
- Candidiasis - Pipeline by Wellstat Vaccines LLC, H1 2017
- Candidiasis - Dormant Projects, H1 2017
- Candidiasis - Dormant Projects, H1 2017 (Contd..1), H1 2017
- Candidiasis - Dormant Projects, H1 2017 (Contd..2), H1 2017
- Candidiasis - Discontinued Products, H1 2017
List of Figures
- Number of Products under Development for Candidiasis, H1 2017
- Number of Products under Development by Companies, H1 2017
- Number of Products under Development by Universities/Institutes, H1 2017
- Number of Products by Top 10 Targets, H1 2017
- Number of Products by Stage and Top 10 Targets, H1 2017
- Number of Products by Top 10 Mechanism of Actions, H1 2017
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
- Number of Products by Top 10 Routes of Administration, H1 2017
- Number of Products by Stage and Top 10 Routes of Administration, H1 2017
- Number of Products by Top 10 Molecule Types, H1 2017
- Number of Products by Stage and Top 10 Molecule Types, H1 2017
